Tissue | Expression Dynamics | Abbreviation |
Liver | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Liver/ERF_pca_on_diff_genes.png) | HCC: Hepatocellular carcinoma |
NAFLD: Non-alcoholic fatty liver disease |
Oral Cavity | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/OralCavity/ERF_pca_on_diff_genes.png) | EOLP: Erosive Oral lichen planus |
LP: leukoplakia |
NEOLP: Non-erosive oral lichen planus |
OSCC: Oral squamous cell carcinoma |
Skin | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Skin/ERF_pca_on_diff_genes.png) | AK: Actinic keratosis |
cSCC: Cutaneous squamous cell carcinoma |
SCCIS:squamous cell carcinoma in situ |
Thyroid | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Thyroid/ERF_pca_on_diff_genes.png) | ATC: Anaplastic thyroid cancer |
HT: Hashimoto's thyroiditis |
PTC: Papillary thyroid cancer |
GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
GO:000630212 | Thyroid | ATC | double-strand break repair | 110/6293 | 251/18723 | 4.48e-04 | 2.65e-03 | 110 |
GO:190122421 | Thyroid | ATC | positive regulation of NIK/NF-kappaB signaling | 37/6293 | 69/18723 | 4.80e-04 | 2.81e-03 | 37 |
GO:0070202110 | Thyroid | ATC | regulation of establishment of protein localization to chromosome | 10/6293 | 12/18723 | 5.84e-04 | 3.34e-03 | 10 |
GO:009034211 | Thyroid | ATC | regulation of cell aging | 33/6293 | 61/18723 | 7.76e-04 | 4.28e-03 | 33 |
GO:007020015 | Thyroid | ATC | establishment of protein localization to telomere | 12/6293 | 16/18723 | 8.59e-04 | 4.68e-03 | 12 |
GO:005109122 | Thyroid | ATC | positive regulation of DNA-binding transcription factor activity | 111/6293 | 260/18723 | 1.32e-03 | 6.88e-03 | 111 |
GO:190495013 | Thyroid | ATC | negative regulation of establishment of protein localization | 61/6293 | 131/18723 | 1.38e-03 | 7.16e-03 | 61 |
GO:005134629 | Thyroid | ATC | negative regulation of hydrolase activity | 155/6293 | 379/18723 | 1.64e-03 | 8.23e-03 | 155 |
GO:00718242 | Thyroid | ATC | protein-DNA complex subunit organization | 103/6293 | 241/18723 | 1.84e-03 | 9.03e-03 | 103 |
GO:014005314 | Thyroid | ATC | mitochondrial gene expression | 51/6293 | 108/18723 | 2.26e-03 | 1.06e-02 | 51 |
GO:0009755110 | Thyroid | ATC | hormone-mediated signaling pathway | 83/6293 | 190/18723 | 2.34e-03 | 1.09e-02 | 83 |
GO:003313512 | Thyroid | ATC | regulation of peptidyl-serine phosphorylation | 65/6293 | 144/18723 | 2.57e-03 | 1.18e-02 | 65 |
GO:000941027 | Thyroid | ATC | response to xenobiotic stimulus | 184/6293 | 462/18723 | 2.70e-03 | 1.23e-02 | 184 |
GO:2000772 | Thyroid | ATC | regulation of cellular senescence | 28/6293 | 53/18723 | 3.01e-03 | 1.36e-02 | 28 |
GO:00062756 | Thyroid | ATC | regulation of DNA replication | 50/6293 | 107/18723 | 3.25e-03 | 1.46e-02 | 50 |
GO:00510531 | Thyroid | ATC | negative regulation of DNA metabolic process | 57/6293 | 125/18723 | 3.47e-03 | 1.55e-02 | 57 |
GO:003806122 | Thyroid | ATC | NIK/NF-kappaB signaling | 64/6293 | 143/18723 | 3.53e-03 | 1.57e-02 | 64 |
GO:003220511 | Thyroid | ATC | negative regulation of telomere maintenance | 20/6293 | 35/18723 | 3.56e-03 | 1.57e-02 | 20 |
GO:19019851 | Thyroid | ATC | positive regulation of protein acetylation | 24/6293 | 45/18723 | 4.97e-03 | 2.03e-02 | 24 |
GO:00080893 | Thyroid | ATC | anterograde axonal transport | 26/6293 | 50/18723 | 5.51e-03 | 2.24e-02 | 26 |
Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
ERF | SNV | Missense_Mutation | novel | c.260N>G | p.Tyr87Cys | p.Y87C | P50548 | protein_coding | deleterious(0) | probably_damaging(0.999) | TCGA-4H-AAAK-01 | Breast | breast invasive carcinoma | Female | <65 | III/IV | Chemotherapy | cyclophosphamide | CR |
ERF | SNV | Missense_Mutation | | c.1541N>A | p.Arg514His | p.R514H | P50548 | protein_coding | deleterious_low_confidence(0) | possibly_damaging(0.511) | TCGA-A8-A06X-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
ERF | SNV | Missense_Mutation | rs368169058 | c.427N>T | p.Arg143Cys | p.R143C | P50548 | protein_coding | deleterious(0) | probably_damaging(0.928) | TCGA-W8-A86G-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Hormone Therapy | arimidex | SD |
ERF | SNV | Missense_Mutation | | c.610N>A | p.Pro204Thr | p.P204T | P50548 | protein_coding | tolerated(0.53) | benign(0.362) | TCGA-C5-A1BQ-01 | Cervix | cervical & endocervical cancer | Female | >=65 | III/IV | Chemotherapy | cisplatin | CR |
ERF | SNV | Missense_Mutation | | c.1471N>A | p.Asp491Asn | p.D491N | P50548 | protein_coding | deleterious(0) | possibly_damaging(0.746) | TCGA-EK-A2PG-01 | Cervix | cervical & endocervical cancer | Female | >=65 | I/II | Unknown | Unknown | SD |
ERF | SNV | Missense_Mutation | | c.1513N>C | p.Glu505Gln | p.E505Q | P50548 | protein_coding | tolerated_low_confidence(0.79) | benign(0.014) | TCGA-EK-A2RB-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Unknown | Unknown | SD |
ERF | SNV | Missense_Mutation | novel | c.1519G>A | p.Glu507Lys | p.E507K | P50548 | protein_coding | deleterious_low_confidence(0) | benign(0.007) | TCGA-VS-A958-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Chemotherapy | cisplatin | CR |
ERF | SNV | Missense_Mutation | | c.1628N>C | p.Leu543Pro | p.L543P | P50548 | protein_coding | deleterious_low_confidence(0) | probably_damaging(0.996) | TCGA-A6-3809-01 | Colorectum | colon adenocarcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
ERF | SNV | Missense_Mutation | rs767080643 | c.616N>A | p.Ala206Thr | p.A206T | P50548 | protein_coding | tolerated(0.43) | benign(0.082) | TCGA-AA-3492-01 | Colorectum | colon adenocarcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
ERF | SNV | Missense_Mutation | novel | c.502N>C | p.Ser168Pro | p.S168P | P50548 | protein_coding | tolerated(0.09) | possibly_damaging(0.763) | TCGA-AA-3877-01 | Colorectum | colon adenocarcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |